大肿瘤异质性放射免疫治疗:晚期非小细胞肺癌的Ⅰ期试验
该Ⅰ期试验(NCT05615142,iERT-01)采用3+3剂量递增设计,评估异质性放疗(EclipseRT)联合αPD-1(iERT)治疗晚期大肿瘤非小细胞肺癌的安全性与可行性。9例患者中未观察到剂量限制性毒性,客观缓解率55.6%,中位无进展生存期12.6个月,中位总生存期26.4个月。
要点
- iERT在晚期大肿瘤NSCLC中耐受良好,无剂量限制性毒性。
- 客观缓解率55.6%,中位PFS 12.6个月,中位OS 26.4个月。
- 不良反应均为1或2级,需更大样本优化剂量方案进一步验证。
核心结论
- iERT在晚期大肿瘤非小细胞肺癌的Ⅰ期试验中显示出良好的安全性和可行性。
- 仍需更大样本及优化剂量方案的研究进一步验证该新策略。
研究设计与样本
- Ⅰ期试验(NCT05615142,iERT-01),采用3+3剂量递增设计。
- 纳入9例Ⅳ期NSCLC伴大肿瘤(>5 cm)患者,标准治疗失败、不适合或拒绝标准治疗。
- iERT为1至3次10 Gy立体定向体部放疗联合2 Gy低剂量放疗及抗PD-1治疗。
主要发现
- 中位随访22.3个月,未观察到剂量限制性毒性。
- 7/9例(77.8%)发生至少1次不良事件,7/9例(77.8%)发生治疗相关不良事件,均为1或2级。
- 客观缓解率55.6%(5/9),中位无进展生存期12.6个月,中位总生存期26.4个月。
关键数值与推荐
- 主要终点为安全性和耐受性;关键次要终点包括客观缓解率、无进展生存期和总生存期。
- 大肿瘤定义为>5 cm;放疗剂量为10 Gy立体定向体部放疗联合2 Gy低剂量放疗,分1至3次。
临床怎么用
- 对于标准治疗失败、不适合或拒绝标准治疗的Ⅳ期NSCLC大肿瘤患者,iERT可能是一种耐受性良好的治疗选择。
- 治疗相关不良事件以1或2级为主,未出现剂量限制性毒性。
局限性
- 样本量小(9例),为Ⅰ期剂量递增试验。
- 需更大队列及优化剂量方案进一步验证疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Inoperable bulky tumors remain challenging to treat with chemotherapy, radiation therapy (RT), or immune checkpoint inhibitors. We developed a novel heterogeneous RT technique with an eclipse-shaped dose distribution (EclipseRT, ERT) by embedding partial-tumor stereotactic body RT (immunogenic) within a low-dose RT (immunomodulatory) field targeting the gross tumor volume. In our previous study, we demonstrated that ERT plus anti-programmed cell death protein 1 (αPD-1) (iERT) activated the natural killer/DC/CD8⁺ T-cell axis, triggering potent antitumor immunity against bulky tumors in mouse tumor models. Here, we report a phase 1 trial to evaluate the safety and feasibility of iERT for advanced non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: This phase 1 trial (NCT05615142, iERT-01) employed a 3 + 3 dose-escalation design. Patients with stage IV NSCLC and bulky tumors (>5 cm) who had failed standard therapy, were ineligible for standard therapy, or declined standard therapy were enrolled. iERT was delivered in 1 to 3 fractions of 10 Gy stereotactic body RT plus 2 Gy low-dose RT with anti-programmed cell death protein 1 (αPD-1). The primary endpoint of the iERT-01 trial was safety and tolerability. Key secondary endpoints included objective response rate, progression-free survival, and overall survival. RESULTS: A total of 9 patients with bulky NSCLC were included. The median follow-up was 22.3 months. iERT was well tolerated, with no dose-limiting toxicities observed. Overall, 7 of 9 patients (77.8%) experienced at least 1 adverse event, and 7 of 9 (77.8%) experienced treatment-related adverse events, all of which were grade 1 or 2. Moreover, it demonstrated encouraging antitumor activity, achieving an objective response rate of 55.6% (5 of 9), with a median progression-free survival of 12.6 months and a median overall survival of 26.4 months. CONCLUSIONS: iERT demonstrated favorable safety and feasibility in this phase 1 trial for advanced bulky NSCLC. Larger-cohort studies with optimized dose regimens are still warranted to further validate the novel strategy.
引用
- Luo R, Liu S, Yan J, et al. Heterogeneous Radioimmunotherapy for Bulky Tumors: A Phase 1 Trial for Advanced Non-Small Cell Lung Cancer. Adv Radiat Oncol. 2026. PMID: 42824609. doi:10.1016/j.adro.2026.102180
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。